Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
During DNA replication p protein binds PCNA in
2019-12-02

During DNA replication p21 protein binds PCNA, in its role as processivity factor, to stop replication when there is DNA damage, and apparently p21 also binds PCNA when this is in complex with Cyc/CDKs [11]. In plants, KRPs (functional analogs of p21), inhibit kinase activity in CycD/CDKs complexes
-
In contrast exposure of CRF
2019-12-02

In contrast, exposure of CRF2(a) receptors to h/rCRF in living cells produced a strikingly weak translocation of βarrestin2 to the membrane. Specifically, we found a markedly lower magnitude and slower rate of βarrestin2 recruitment to CRF2(a) receptors in response to h/rCRF concentrations as high a
-
Cefotaxime sodium salt Cholesterol homeostasis is maintained
2019-12-02

Cholesterol homeostasis is maintained through a tight regulation between endogenous de novo synthesis, dietary absorption, utilization and excretion of bile salts. The Cefotaxime sodium salt of cholesterol from the intestine constitutes the central part of cholesterol homeostasis in the body [41]. I
-
br Agonist binding ETA activation is
2019-12-02

Agonist binding ETA activation is promoted by binding of the endogenous peptidergic agonists to their orthosteric binding site on the receptor. ET1 and ET2 (Trp6-Leu7-ET1) bind with equal high affinity to ETA, whereas the third endogenous isopeptide ET3 (Thr2-Phe4-Thr5-Tyr6-Lys7-Tyr14-ET1) binds
-
Adding MPA or NETA we found no
2019-12-02

Adding MPA or NETA we found no impact on the estradiol-induced downregulation of serum-stimulated endothelin synthesis in vitro [40]. Progesterone was also able to inhibit the angiotensin II-induced increase in endothelin production [41]. Several clinical studies on the effect of oral or transdermal
-
The expression profiles of NCK and ABI genes
2019-12-02

The expression profiles of NCK and ABI genes after ESC bacterial infection were determined. As shown in Fig. 1a, NCK1, ABI2a and ABI2b were significantly induced after ESC infection. While, ABI3a was significantly downregulated. Intestine was confirmed as a site of E. ictaluri entry by bacteriologic
-
Recent studies have reported that miR
2019-12-02

Recent studies have reported that miR-454 plays an important role in various cellular processes and diseases, such as inflammation, infection, osteogenic differentiation, and cancers [25,27,29,30]. Multiple evidence has documented that miR-454 promotes the proliferation, migration and invasion, and
-
In normal chow fed mice EP deficiency also decreased the
2019-12-02

In normal chow fed mice, EP4 deficiency also decreased the expression of CYP8B1, the downstream target of CYP7A1. Similarly, knockdown of EP4 with small interfering RNA reduced the expression of CYP8B1 in HepG2 cells. Therefore, it was anticipated that there would be an increased expression of CYP8B
-
It has been reported that PGE increases expression of
2019-12-02

It has been reported that PGE2 increases expression of the survivin mRNA (Baratelli et al. 2005) and promotes the stabilization of the survivin protein in some tumor Tenovin-3 receptor (Krysan et al. 2003). However, it is unclear whether PGE2 affects the expression of survivin mRNA or promotes the s
-
In the present study we combined activity based protein
2019-11-30

In the present study, we combined activity-based protein profiling, biochemical and genetic approaches to identify the PLCPs involved in the sphingolipid pathway leading to plant PCD. By using Arabidopsis Schindler list and leaves, we demonstrate that this sub-class of plant proteases is activated
-
Almost of drugs in the market undergo deactivation though
2019-11-30

Almost 75% of drugs in the market undergo deactivation though oxidation, reduction or hydrolysis by cytochrome P450 (CYP) enzymes, and then, either directly or by facilitated excretion from the body (Guengerich, 2008). The CYP3A subfamily is of particular interest because of its broad substrate spe
-
br NF B and STAT as Regulators of
2019-11-30

NF-κB and STAT as Regulators of the CDK System While current data support the concept that CDKs augment the proinflammatory activity of NF-κB, our understanding of the function of this transcription factor system in CDK regulation remains patchy. Seminal studies showed the contribution of NF-κB t
-
N6-Methyl-ATP Treatment related adverse events have
2019-11-30

Treatment-related adverse events have been a serious issue in clinical application. Severe toxicity has been reported in clinical trials using antibody blockade of CSF-1R (20 mg/kg), PD-1, and CTLA-4.29, 30, 31 However, apparent side effects were not observed in our study with PLX3397 treatment alon
-
br Acknowledgments The authors thank Elisabete Lepera and Ro
2019-11-30

Acknowledgments The authors thank Elisabete Lepera and Rosana Silva for technical support. The study was supported by FAPESP, CNPq and PADC/FCF-UNESP. T.T. Miguel was the recipient of a FAPESP (Proc. 05/05171-1) and R.L. Nunes-de-Souza of a CNPq (Proc. 303580/2009-7) fellowship. Introduction
-
KN-93 Phosphate br Method Detailed study protocol was report
2019-11-30

Method Detailed study protocol was reported previously. The ULTIMATE- HFrEF trial was approved by the Institutional Review Board of our hospital, and the study drug, udenafil, was approved as Investigational New Drug for treatment in patients with chronic HFrEF by Ministry of Food and Drug Safety
16105 records 950/1074 page Previous Next First page 上5页 946947948949950 下5页 Last page